<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01062490</url>
  </required_header>
  <id_info>
    <org_study_id>MC-FludT.8/MDS</org_study_id>
    <nct_id>NCT01062490</nct_id>
  </id_info>
  <brief_title>Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)</brief_title>
  <official_title>Clinical Phase II Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>medac GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, multinational, non-randomized, non-controlled open-label phase II
      trial to evaluate the safety and efficacy of treosulfan in a combination regimen with
      fludarabine as conditioning therapy prior to allogeneic stem cell transplantation (SCT) in
      patients with MDS.

      The aim is to demonstrate a clinical benefit compared to historical data with intravenous
      busulfan.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Evaluation of engraftment</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Evaluation of CTC grade 3 and 4 adverse events between Day -6 and Day +28: hyperbilirubinemia and mucositis/stomatitis, veno-occlusive disease, seizures</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Treosulfan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with myelodysplastic syndrome, (MDS) according to WHO classification (&lt; 20 % myeloblasts in peripheral blood or bone marrow at initial diagnosis) indicated for allogeneic transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treosulfan</intervention_name>
    <description>14 g/m2/d, day -6 to -4</description>
    <arm_group_label>Treosulfan</arm_group_label>
    <other_name>Ovastat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with myelodysplastic syndrome, (MDS) according to WHO classification (&lt; 20 %
             myeloblasts in peripheral blood or bone marrow at initial diagnosis) indicated for
             allogeneic transplantation

          2. Availability of an HLA-identical sibling donor (MRD) or HLA-identical unrelated donor
             (MUD) HLA-identity defined by the following markers: HLA-A, -B, -DRB1, DQB1.

          3. Target graft size (unmanipulated) bone marrow: 2 to 10 x 106 CD34+ cells/kg BW
             recipient or at least 2 x 108 nucleated cells /kg BW or peripheral blood: 4 to 10 x
             106 CD34+ cells/kg BW recipient

          4. Age &gt; 18 and &lt; 60 years

          5. Karnofsky Index &gt; 80 %

          6. Adequate contraception in female patients of child-bearing potential

          7. Written informed consent

        Exclusion Criteria:

          1. 'Secondary' or therapy-related MDS with known history of exposure to cytotoxic
             alkylating drugs and/or radiation therapy

          2. Previous AML-induction therapy with more than two courses (e.g. in case of blast
             excess)

          3. Previous allogeneic transplantation

          4. Severe concomitant illnesses / medical conditions (e.g. impaired respiratory and/or
             cardiac function)

          5. Known and manifested malignant involvement of the CNS

          6. Active infectious disease

          7. HIV- positivity or active hepatitis infection

          8. Impaired liver function (Bilirubin &gt; upper normal limit; Transaminases &gt; 3.0 x upper
             normal limit)

          9. Impaired renal function (Creatinine-clearance &lt; 60 ml/min; Serum Creatinine &gt; 1.5 x
             upper normal limit).

         10. Pleural effusion or ascites &gt; 1.0 L

         11. Pregnancy or lactation

         12. Known hypersensitivity to treosulfan and/or fludarabine

         13. Participation in another experimental drug trial within 4 weeks before study

         14. Non-co-operative behaviour or non-compliance

         15. Psychiatric diseases or conditions that might impair the ability to give informed
             consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tapani Ruutu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biomedicum Helsinki 2 C, POB 705, Turkholmankatu 8 C, FIN-00029 HUS Helsinki, Finland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2010</study_first_submitted>
  <study_first_submitted_qc>February 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2010</study_first_posted>
  <last_update_submitted>February 3, 2010</last_update_submitted>
  <last_update_submitted_qc>February 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Joachim Baumgart, PhD</name_title>
    <organization>medac Gesellschaft f√ºr klinische Spezialpraeparate mbH</organization>
  </responsible_party>
  <keyword>Treosulfan</keyword>
  <keyword>MDS</keyword>
  <keyword>allogeneic stem cell transplantation</keyword>
  <keyword>leukemia</keyword>
  <keyword>Conditioning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treosulfan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

